Solving Cancer Together, a Message from the Director

The new CCTG Strategic Plan 2022-2027

A vision of a future where a cancer diagnosis is no longer a burden on Canadians

Everyone has been touched by cancer either through their own journey or supporting a loved one. Despite better treatments and outcomes, the physical, emotional, and economic burden on patients, their families, and caregivers is likely to increase due to an aging population. In addition,  the environment in which trials are conducted is becoming more complex. New therapies, biomarkers, and patient reported outcomes are changing the design, the type of data and the requirements for trial conduct and oversight. 


Our new Strategic Plan: Solving Cancer Together articulates the scientific priorities and required supporting activities that would lead the Group through to 2027. The plan was developed iteratively with our research leaders, investigators, patients, research staff and stakeholders. Our new scientific priorities: Understand Cancer Biology, Reduce the Cancer Burden, and Improve Cancer Care with their associated objectives and activities will lead to new advances in innovative therapies, understanding resistance, reduce the burdens of cancer, and show the value of these innovations. We are keenly focused on ensuring equity, diversity, and inclusivity across our group and within our research activities.

The result of this planning process is an ambitious scientific agenda — #SolvingCancerTogether that aligns with our vision of a future where a cancer diagnosis is no longer a burden on Canadians, and where the results of CCTG trials will identify cancer treatments that are effective, accessible, and affordable for all.

en français

Janet Dancey, MD, FRCPC
Director, Canadian Cancer Trials Group


The best evidence to inform Canadian clinical practice and policy comes from clinical trials organized around questions raised by the Canadian research community and answered through trials designed and executed in Canada. Engaging the international community ensures rapid completion and broad application of results but internationally led trials do not take into account the specifics of the Canadian healthcare system.